IP Verse

Antiviral Therapy - EP3127542

The patent EP3127542 was granted to Viiv Healthcare on Aug 22, 2018. The application was originally filed on Jan 24, 2011 under application number EP16187411A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3127542

VIIV HEALTHCARE
Application Number
EP16187411A
Filing Date
Jan 24, 2011
Status
Opposition Rejected
Dec 20, 2024
Grant Date
Aug 22, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZMay 22, 2019TER MEER STEINMEISTER & PARTNERADMISSIBLE
STADA ARZNEIMITTELMay 22, 2019HAMM & WITTKOPPADMISSIBLE
TEVA PHARMACEUTICALSMay 22, 2019D YOUNGADMISSIBLE
COOKEMay 20, 2019ELKINGTON AND FIFEADMISSIBLE

Patent Citations (51) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS5034394
DESCRIPTIONUS5047407
DESCRIPTIONUS5089500
DESCRIPTIONUS5519021
DESCRIPTIONUS5641889
DESCRIPTIONUS5663169
DESCRIPTIONUS5663320
DESCRIPTIONUS5693787
DESCRIPTIONUS5696254
DESCRIPTIONUS5808147
DESCRIPTIONUS5811423
DESCRIPTIONUS5840990
DESCRIPTIONUS5849911
DESCRIPTIONUS5905082
DESCRIPTIONUS5914332
DESCRIPTIONUS5917041
DESCRIPTIONUS5917042
DESCRIPTIONUS5919941
DESCRIPTIONUS5922695
DESCRIPTIONUS5935946
DESCRIPTIONUS5977089
DESCRIPTIONUS6043230
DESCRIPTIONUS6051709
DESCRIPTIONUS6069249
DESCRIPTIONUS6087383
DESCRIPTIONUS6087501
DESCRIPTIONUS6281367
DESCRIPTIONUS6294540
DESCRIPTIONUS6329522
DESCRIPTIONUS6340587
DESCRIPTIONUS6392085
DESCRIPTIONUS6436989
DESCRIPTIONUS6448403
DESCRIPTIONUS6514953
DESCRIPTIONUS6552193
DESCRIPTIONUS6555133
DESCRIPTIONUS6555687
DESCRIPTIONUS6639071
DESCRIPTIONUS6646125
DESCRIPTIONUS6870053
DESCRIPTIONUS6939964
DESCRIPTIONUS7109228
DESCRIPTIONUS7119202
DESCRIPTIONUS7534809
OPPOSITIONEP1874117
OPPOSITIONUS7511037
OPPOSITIONWO2006116764
SEARCHUS2006084627
SEARCHUS2009318421
SEARCHWO2009148600
SEARCHWO2010011812

Non-Patent Literature (NPL) Citations (32) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- PHARMACEUTICAL RESEARCH, (1986), vol. 3, no. 6, page 318
DESCRIPTION- SELLESETH, D.W. ET AL., ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (2003), vol. 47, pages 1468 - 1471
EXAMINATION- REGISTRY, CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US, (20080922), Database accession no. 1051375-16-6
EXAMINATION- MIN ET AL, "Pharmacokinetics and Safety of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor, in Healthy Volunteers", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, (20091102), vol. 54, no. 1, pages 254 - 258, XP055280415
OPPOSITION- (20100121), URL: https://clinicaltrials.gov/ct2/history/NCT00951015?A=9&B=9&C=merged#StudyPageTop, (20190514), XP055600260
OPPOSITION- Anonymous, "A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects (ING11276)", Internet Archive Wayback Machine, (20090904), URL: https://web.archive.org/web/20090904062433/http://clinicaltrials.gov/ct2/show/NCT00951015, XP055598041
OPPOSITION- Anonymous, "Antiviral activity of S/GSK1349572, the only once-daily, unboosted integrase inhibitor in clinical development, evaluated in phase 2 study", GSK press release, (20090700), XP055544606
OPPOSITION- Anonymous, "EPZICOMâ„¢ Prescribing Information", (20070000), pages 3 - 28
OPPOSITION- "Antiviral activity of S/GSK1349572, the only once-daily, unboosted integrase inhibitor in clinical development, evaluated in phase 2 study", GSK press release, (20090700), XP055544606
OPPOSITION- ARRIBAS et al., "Once-daily S/GSK1349572 as part of combination therapy in antiretroviral naïve adults: rapid and potent antiviral responses in the interim 16 week- analysis from SPRING-1 (ING112276)", XVIII International Aids Conference, Vienna, Austria, (20100718), XP055275419
OPPOSITION- Dhhs, "Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents", Office of AIDS Research Advisory Council (OARAC), (20091201), pages 1 - 161, XP055275315
OPPOSITION- Drug Data Report, (20101000), vol. 32, no. 9, pages 893 - 895, XP055280507
OPPOSITION- "EPZICOM (abacavir sulfate and lamivudine) Tablets, for oral use", Prescribing information for Epzicom, (201203), XP055600307
OPPOSITION- "EPZICOMâ„¢ Prescribing Information", NDA 21-652, (20040000), pages 5 - 26
OPPOSITION- FDA, "patient information leaflet", ISENTRESS (raltegravir) Tablets;, (20090700), XP055600305
OPPOSITION- JOHNS et al., "The Discovery of S/GSK1349572: A Once Daily Next Generation Integrase Inhibitor with a Superior Resistance Profile", 17th CROI, Conference on Retroviruses and Opportunistic Infections,, (20100200), XP055275444
OPPOSITION- JOHNS et al., "The Discovery of S/GSK1349572: A Once Daily Next-Generation Integrase Inhibitor with a Superior Resistance Profile", 17th CROIt, Conference on Retroviruses and Opportunistic Infections, San Francisco CA, (20100216), XP055539843
OPPOSITION- LALEZARI et al., "Potent Antiviral Activity of S/GSK1349572, A Next Generation D3 Integrase Inhibitor (INI) , in IN 1-Naïve HIV-1 -Infected Patients: ING111521 Protocol", IAS 2009 - 5th Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town South Africa, (20090719), XP055280561
OPPOSITION- REGISTRY, CAS, (20080922), Database accession no. RN 1051375-16-6, XP055600264
OPPOSITION- UNDERWOOD et al., "S/GSK1349572: A Next Generation integrase Inhibitor with Activity Against Integrase Inhibitor-Resistant Clinical Isolates from Patients D5 Experiencing Virologic Failure while on Raltegravir Therapy", IAS 2009 - 5th Conference on HIV Pathogenesis, Cape Town South Africa, (20090719), XP055544612
OPPOSITION- "WHO Model List of Essential Medicines", World Health Organization's 16th List of Essential Medicines, (20093000), XP055600280
OPPOSITION- Hammer et al., "Antiretroviral Treatment of Adult HIV Infection 2008 Recommendations of the International AIDS Society", JAMA, (20080806), vol. 300, no. 5, pages 555 - 570, XP008134902
OPPOSITION- DAMOND et al., "Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients", AIDS, (20080000), vol. 22, no. 5, pages 665 - 666, XP055280519
OPPOSITION- TRICOT et al., "Safety and Efficacy of Raltegravir in HIV-Infected Transplant Patients Cotreated with Immunosuppressive Drugs", AMERICAN JOURNAL OF TRANSPLANTATION, (20090801), vol. 9, no. 8, pages 1946 - 1952, XP055275441
OPPOSITION- KOBAYASHI et al., "In Vitro Antiretroviral Properties of S/GSK1349572, a Next- Generation HIV Integrase Inhibitor", Antimicrob. Agents Chemother., (20110200), vol. 55, no. 2, doi:doi:10.1128/AAC.01209-10, pages 813 - 821, XP002680283
OPPOSITION- GARVEY et al., "The Naphthyridinone GSK364735 Is a Novel, Potent Human Immunodeficiency Virus Type 1 Integrase Inhibitor and Antiretroviral", Antimicrobial Agents and Chemotherapy, (20080300), vol. 52, no. 3, pages 901 - 908, XP055600300
OPPOSITION- ROCKSTROH K.J., "Integrase inhibitors: Why do we need a new drug class for HIV therapy?", Eur J Med Res, (20091124), vol. 14, no. suppl. III, pages 1 - 3, XP021130215
OPPOSITION- YOUNG et al., "A Pilot Study of Abacavir/Lamivudine and Raltegravir in Antiretroviral-Naïve HIV-1-Infected Patients: 48-Week Results of the SHIELD Trial", HIV Clin Trials., (20101000), vol. 11, no. 5, pages 260 - 269, XP055275323
OPPOSITION- Patricia Pecora Fulco; Et Al, "Raltegravir-Based HAART Regimen in a Patient with Large B-Cell Lymphoma", The Annals of Pharmacotherapy, (20100000), vol. 44, pages 377 - 382, XP055280525
OPPOSITION- SOMBOONWIT et al., "Abacavir and lamivudine combination", Expert. Opin. Drug Metab. Toxicol., (20091200), vol. 5, no. 12, doi:doi:10.1517/17425250903439720, pages 1599 - 1606, XP055275319
SEARCH- Anonymous, "A Phase IIb Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects", (20090731), page 5PP, ClinicalTrials.gov archive, URL: https://clinicaltrials.gov/archive/NCT00951015/2009_07_31, (20161118), XP002764380 [X] 1-10 * the whole document *
SEARCH- SONG I et al, "The Effect of Ritonavir-Boosted Protease Inhibitors on the HIV Integrase Inhibitor, S/GSK1349572, in Healthy Subjects", (20090915), INTERNET, URL: http://www.natap.org/2009/ICCAC/ICCAC_52.htm, (20130521), XP002697436 [A] 1-10 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents